Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs 7,238
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Pipeline programs

Page 58 of 151

  1. Fostamatinib Disodium tablet 100 mg

    RIGEL PHARMACEUTICALS INC

    IGA Nephropathy

    phase 2 small molecule terminated

    1 trial

  2. Fostamatinib disodium (R935788)

    RIGEL PHARMACEUTICALS INC

    Rheumatoid Arthritis

    phase 2 small molecule completed

    2 trials

  3. Fp MDPI

    Teva Pharma GmbH

    Asthma

    phase 2 small molecule completed

    3 trials

  4. Freeze-dried, Capsulized FMT

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Slow Transit Constipation

    phase 2 other active

    1 trial

  5. Fremanezumab

    Teva Pharma GmbH

    Post-Traumatic Headache

    phase 2 small molecule completed

    1 trial

  6. Fremanezumab

    Teva Pharma GmbH

    Fibromyalgia

    phase 2 small molecule terminated

    1 trial

  7. Fresh Frozen Plasma (FFP)

    United Therapeutics Europe Ltd

    Anticoagulant Reversal

    phase 2 mab terminated

    1 trial

  8. Frexalimab, Matched Placebo for Test

    Sanofi-aventis Healthcare Pty Ltd

    Systemic lupus erythematosus

    phase 2 small molecule active

    1 trial

  9. Fruquintinib

    Dai, Guanghai

    Colorectal Cancer Metastatic

    phase 2 small molecule active

    1 trial

  10. Fruquintinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Fruquintinib

    phase 2 small molecule active

    1 trial

  11. Fruquintinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Rectal Cancer

    phase 2 small molecule active

    1 trial

  12. Fruquintinib

    RenJi Hospital

    Stomach Neoplasms

    phase 2 small molecule active

    1 trial

  13. Fruquintinib Combined With Chemotherapy

    Takeda

    Metastatic Colorectal Cancer (CRC)

    phase 2 small molecule active

    1 trial

  14. Full Spectrum Microbiota

    Finch Therapeutics Group

    Clostridium Difficile Infection Recurrence

    phase 2 small molecule completed

    1 trial

  15. Full dose preparation

    CUMBERLAND PHARMACEUTICALS INC

    Colonoscopy Preparation

    phase 2 small molecule completed

    1 trial

  16. Fulvestrant

    United Therapeutics Europe Ltd

    Advanced Breast Cancer

    phase 2 small molecule active

    1 trial

  17. Fulvestrant

    Syndax Pharmaceuticals

    Breast Cancer

    phase 2 small molecule terminated

    1 trial

  18. Fulvestrant

    ATOSSA THERAPEUTICS, INC.

    Female Breast Carcinoma

    phase 2 small molecule terminated

    1 trial

  19. Fulvestrant with Enzalutamide

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  20. Functional Precision Oncology

    United Therapeutics Europe Ltd

    Breast Cancer Recurrent

    phase 2 other active

    1 trial

  21. Furmonertinib

    Shanghai University of Traditional Chinese Medicine

    Lung Adenocarcinoma Stage III

    phase 2 small molecule active

    1 trial

  22. Furmonertinib

    The First People's Hospital of Lianyungang

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  23. Furmonertinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Adenocarcinoma Stage III

    phase 2 small molecule active

    1 trial

  24. Furmonertinib

    Peking University People's Hospital

    Adenocarcinoma of Lung

    phase 2 small molecule active

    1 trial

  25. Furmonertinib in combination with Anrotinib and chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  26. Furoic acid loperamide hydrochloride cream

    Universal Integrated

    Eczema

    phase 2 small molecule active

    1 trial

  27. G-202

    BRIGHT MINDS BIOSCIENCES INC.

    Glioblastoma Multiforme

    phase 2 small molecule completed

    1 trial

  28. G-Pen Mini™ (glucagon injection)

    Xeris Biopharma Holdings

    Hypoglycemia

    phase 2 small molecule completed

    1 trial

  29. G-Pen Mini™ (glucagon injection)

    Xeris Biopharma Holdings

    Diabetes Mellitus, Type 1

    phase 2 small molecule completed

    2 trials

  30. G-Pen(TM) 1 mg

    Xeris Biopharma Holdings

    Hypoglycemia

    phase 2 small molecule completed

    1 trial

  31. G-Pump™ (glucagon infusion)

    Xeris Biopharma Holdings

    Hypoglycemia

    phase 2 small molecule completed

    1 trial

  32. G03-52-01

    United Therapeutics Europe Ltd

    Healthy

    phase 2 small molecule completed

    1 trial

  33. G100

    Lxo Ireland Designated Activity Company

    Follicular Low Grade Non-Hodgkin's Lymphoma

    phase 2 small molecule terminated

    1 trial

  34. GA-GCB

    Takeda

    Gaucher Disease

    phase 2 small molecule completed

    1 trial

  35. GADOTERIC ACID, [18F]fludarabine

    Pari Pharma GmbH

    Patients with newly diagnosed primary central nervous system lymphoma naïve to surgery, radiotherapy or chemotherapy

    phase 2 small molecule active

    1 trial

  36. GARM-Autism Adults

    Blackmores Limited

    Autism Spectrum Disorder

    phase 2 mab active

    1 trial

  37. GC4419

    Galera Therapeutics

    Covid19

    phase 2 small molecule terminated

    1 trial

  38. GC4419

    Galera Therapeutics

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  39. GC4419 (avasopasem manganese)

    Galera Therapeutics

    Esophagitis

    phase 2 small molecule terminated

    1 trial

  40. GC4711 +SBRT

    Galera Therapeutics

    SBRT

    phase 2 small molecule terminated

    1 trial

  41. GCT1015-05

    Genmab A/S

    Recurrent or stage IVB cervical cancer

    phase 2 small molecule active

    1 trial

  42. GCT1042-01

    Genmab A/S

    Malignant solid tumors: Patients with relapsed or refractory, advanced and/or metastatic melanoma, Non-Small Cell Lung Cancer (NSCLC), Head and neck squamous cell carcinoma (HNSCC), Panctreatic ductal adenocarcinoma (PDAC) or Colorectal Cancer (CRC).

    phase 2 small molecule active

    1 trial

  43. GCT1046-01

    Genmab A/S

    Malignant solid tumors: endometrial carcinoma (EC), urothelial carcinoma (UC), triple-negative breast cancer (TNBC), squamous cell carcinoma of the head and neck (SCCHN), or cervical cancer.

    phase 2 small molecule active

    1 trial

  44. GCT1046-04

    Genmab A/S

    Malignant Solid Tumors - Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  45. GCT1046-07

    Genmab A/S

    Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), Metastatic Cutaneous Melanoma (Stage IV)

    phase 2 small molecule active

    1 trial

  46. GCT1055-01

    Genmab A/S

    Malignant Solid Tumors

    phase 2 small molecule active

    1 trial

  47. GCT3013-01

    Genmab A/S

    Lymphoma of B-cell origin

    phase 2 small molecule active

    1 trial

  48. GCT3013-02

    Genmab A/S

    Lymphoma of B-cell origin

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.